Navigation Links
Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
Date:9/12/2007

Over 20 Targanta-Related Posters and Presentations Accepted to Meeting

CAMBRIDGE, Mass., Sept. 12 /PRNewswire/ -- Targanta Therapeutics Corporation today announced that 23 presentations will showcase its lead antibiotic candidate, oritavancin, and its antibiotic drug discovery platform at the upcoming 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place in Chicago, September 17-20, 2007.

Thomas Parr, Ph.D., Chief Scientific Officer of Targanta Therapeutics commented on the meeting: "We are very proud of the body of data being presented on behalf of Targanta at ICAAC this year-a true testament, we believe, to the efforts and expertise of our scientists and collaborators. We continue to be encouraged by the breadth of data supporting the differentiating characteristics of oritavancin and are pleased to be able to present for the first time promising data on our pre-clinical osteomyelitis program."

Throughout the meeting, multiple posters will highlight the in vitro activity of oritavancin, Targanta's investigational antibiotic for the treatment of gram-positive infections, against a wide spectrum of antibiotic susceptible and resistant gram-positive bacteria. In addition, two presentations at ICAAC will highlight Targanta's proprietary drug discovery platform, which utilizes bisphosphonate prodrugs of antibiotics to generate molecules that deliver antibiotics directly to the bone.

The following abstracts have been accepted for poster or slide presentation at ICAAC:

Date Time Number Type Author Title

Monday, 12:00- A-49 Poster Lehoux PK-PD of Oritavancin

Sept. 17 1:00PM CDT (ORI) Against

Streptococcus pneumoniae

(SP) in a Murine-Pneumonia

Infection Model
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Emerging technology companies receive significant funding
3. Genzyme acquistion of Bone Care approved, significant impact forecast
4. BIO 2007: Wisconsin makes its presence felt
5. TDS trades markets to gain Duluth presence
6. West Coast VC Establishes Midwest Presence in Madison
7. Sony Bets Heavy on Wisconsin Digital Entertainment Presence
8. NameProtect releases annual list of top trademarkers
9. Doyle says new contracts saving state more than $16 million annually
10. Department of Commerce offers up to $1 million annually to aid tech entrepreneurs
11. Annual Bioethics Forum to explore genetic testing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...NTACRUZ,Calif.,Nov.24/PRNewswire/--Twomoreprestigi...,sleadingonlinejobboardandcareerssiteforlifescienc...rsityarenowmembersofthejobboard,joining28othermajo...d, www.biocareercenter.com ,isonlyforpost-graduate...ncecareersitesontheInternet,BioCareerCenteristheon...
(Date:11/24/2009)...YKJAVIK,Iceland,November24/PRNewswire-FirstCall/--...hatithasreceivednoticefrom,theNasdaqStockMarkettha...sofNovember30,2009andaForm25-NSEwillbefiledwiththe...CODE,scommonstock,fromlistingonNasdaq,unlessthecom...Panel.Thecompanyhasfiledsuchanappeal,which,willsta...
(Date:11/24/2009)... Health care employment grew by 2...nly one to show consistent growth during the U.S. ...s remain in trouble, and health systems are coming...l, instead of just administrators. , ...re employment continued growing in October despite...
(Date:11/24/2009)...ANGHAI,Nov.24/PRNewswire-Asia/--NODPharmaceuticals...hasallowedthepatentapplicationfor,itsnano-particle...sahighlyefficientapproachtoincorporatepeptidesor,p...eliveryofdrugs,otherwiseadministeredasinjections.N...tomanymacromoleculardrugssuchasinsulin,interferon,...
Breaking Biology Technology:Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4
...ls,Inc. (Nasdaq: CADX ), a biopharmaceutical comp...ializing proprietary product candidates principall... that the company,s,President and CEO Theodore Sch...ew on Tuesday, October 28, 2008 at 9:30am Pacific ...stor Conference at the Hyatt Aventine,La Jolla Hot...
...nounced that it,has provided a GOLD facility for t...) by MTS Health Investors, LLC (MTS). GOLD financi...cilities. Terms of the,transaction were not disclo...e largest and most reputable,DNA testing laborator...dentification testing for the private sector. The ...
...esults (all percentage comparisons are to comparab... Consistent Research Sales Gain: Q3 2008 sales ...3.1% to organic growth of 4.3%. Q3 organic sal...ased sales units was in-line with the 6.9% gain fo...ncy adjusted sales for SAFC decreased by 2.0% ...
Other Biology Technology:Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the BIOCOM Investor Conference 2Golub Capital Provides Debt Financing to Support the Acquisition of DNA Diagnostics Center, Inc. by MTS Health Investors, LLC 2Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 2Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 3Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 4Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 5Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 6Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 7Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 8Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 9Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 10Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 11Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 12Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 13Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 14Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 15Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 16Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 17Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 18Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 19Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 20
(Date:11/25/2009)..., police officers and ambulance workers faced a te...omplex. They battled to save people from the colla... fires and evacuated as many people as they could ...ple. And making their jobs even harder was the pro...d their relatives jammed mobile networks with call...
(Date:11/25/2009)...y be just as vital to your health as what you eat,...gical Studies. Their experiments in mice revealed ...enes in the liverthe body,s metabolic clearinghous...e body,s circadian clock as conventional wisdom ha...y of a large number of genes completely independen...
(Date:11/24/2009)... flabby arteries from collapsing have been true li...no longer needed -- once the arteries are strength... had no choice but to leave them in place. , Pro...tment of Biomedical Engineering has developed a ne... where they,re needed, then dissolves. , "Our ne...
Breaking Biology News(10 mins):Magic box for mission impossible 2Magic box for mission impossible 3Feeding the clock 2Feeding the clock 3A coating for life 2Vandetanib shows clinical benefit when combined with docetaxel for lung cancer 47472 1Vandetanib shows clinical benefit when combined with docetaxel for lung cancer 47472 2Vandetanib shows clinical benefit when combined with docetaxel for lung cancer 47472 3Hispanic children in US at greater risk for obesity than other ethnic racial groups 47469 1Hispanic children in US at greater risk for obesity than other ethnic racial groups 47469 2Is your environment damaging your health 3F New center aims to find out 47466 1Is your environment damaging your health 3F New center aims to find out 47466 2Is your environment damaging your health 3F New center aims to find out 47466 3
...The cell-signaling molecule Akt is a primary trigg...rface to begin growing vertically beneath the skin... have found. Understanding this key molecular dif...e surface of the skin and melanomas that grow vert...r the development of drugs to treat individuals wi...
...A popular game fish mistaken by scientists for a d...ong the reefs of the Abrolhos region of the South ...l Zootaxa announced the discovery of Lutjanus alex...Lutjanidae family, by researchers Rodrigo Moura of...an of Environmental Defense. The study published i...
...A UCL (University College London) study has found ... not think too hard and instead trust your instinc...urnal Current Biology, shows that, in some cases, ...decisions taken using higher-level cognitive proce...dd one out on a screen covered in over 650 identic...
Other Biology News:Molecular differences between early and advanced melanomas could provide new drug targets 2New species of snapper discovered in Brazil 2Trusting your instincts leads you to the right answer 2Trusting your instincts leads you to the right answer 3
Mouse Anti-Human Cystatin A Monoclonal Antibody, Unconjugated, Clone 224705 from R&D Systems
Acc I from Takara Mirus Bio
Microlite 2+ Plate from Thermo Scientific
... low temperature freezers offer a superior sample ...samples with high capacities. Innovative insulatio... excellent warming protection and ensure low energ...fy tracking of sample location and maximize sample...
Biology Products: